Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Axsome Therapeutics (NASDAQ:AXSM) had its price target increased by stock analysts at Morgan Stanley from $247.00 to $249.00 in a report released on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley‘s price target would suggest a potential upside of 73.69% from the stock’s current price.

Several other equities research analysts have also issued reports on AXSM. Mizuho increased their price objective on shares of Axsome Therapeutics from $306.00 to $316.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Needham & Company LLC upped their price target on shares of Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft lowered their price target on Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Royal Bank Of Canada cut their price objective on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Piper Sandler reduced their price objective on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a research note on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $269.89.

Axsome Therapeutics Trading Up 5.4%

Axsome Therapeutics stock traded up $7.35 during midday trading on Tuesday, reaching $143.36. The stock had a trading volume of 804,537 shares, compared to its average volume of 781,953. The stock’s 50-day simple moving average is $183.33 and its 200 day simple moving average is $198.74. Axsome Therapeutics has a twelve month low of $123.00 and a twelve month high of $260.19. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. The stock has a market capitalization of $7.51 billion, a PE ratio of -38.21 and a beta of 0.86.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.38. The company had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. The firm’s revenue was up 51.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.94) earnings per share. Analysts expect that Axsome Therapeutics will post -3.04 EPS for the current year.

Insider Buying and Selling at Axsome Therapeutics

In other news, COO Mark Jacobson sold 10,000 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the completion of the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at approximately $2,086,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Herriot Tabuteau sold 45,004 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $212.01, for a total transaction of $9,541,298.04. Following the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,532,620.29. The trade was a 86.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 59,664 shares of company stock valued at $12,624,805 over the last 90 days. Insiders own 20.60% of the company’s stock.

Institutional Trading of Axsome Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AXSM. BlackRock Inc. acquired a new position in shares of Axsome Therapeutics in the second quarter worth about $759,695,000. First Trust Advisors LP grew its stake in Axsome Therapeutics by 1,230.2% during the 1st quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after purchasing an additional 534,066 shares in the last quarter. Bank of America Corp DE acquired a new stake in Axsome Therapeutics during the 2nd quarter valued at approximately $110,756,000. Canada Pension Plan Investment Board acquired a new stake in Axsome Therapeutics during the 2nd quarter valued at approximately $55,171,000. Finally, Bank of New York Mellon Corp purchased a new stake in Axsome Therapeutics during the 2nd quarter worth approximately $48,275,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Axsome reported third-quarter revenue of $259.7 million, up 51.9% year over year and ahead of the $249.2 million consensus estimate. The company’s adjusted loss of $0.25 per share was substantially better than the expected $0.63 loss and improved from a $0.94 loss a year earlier. Axsome third-quarter results
• Positive Sentiment: Management highlighted sales growth across key brands and pipeline milestones expected in 2027, supporting the longer-term growth narrative. Axsome sales and pipeline update
• Neutral Sentiment: Axsome will participate in several November healthcare investor conferences, including events hosted by Guggenheim, Wolfe Research, Truist and UBS. These presentations could provide further updates on product launches and the pipeline, but do not represent a new operating development. Axsome upcoming investor conferences
• Negative Sentiment: Market concerns about slower-than-expected AUVELITY adoption in Alzheimer’s care appear to outweigh the quarterly beat. Reports indicate incremental growth was driven more by depression prescriptions for patients under 65 than by Alzheimer’s-related prescriptions, raising questions about the durability of near-term growth. AUVELITY launch concerns
• Negative Sentiment: Several analysts lowered their price targets following the results: RBC to $273, Guggenheim to $250, UBS to $239 and Baird to $220, while maintaining positive ratings. The cuts suggest analysts still see substantial upside but are reducing estimates to reflect launch execution and valuation risks. UBS Axsome price-target reduction

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.